Key result
Resistant depression was associated with significantly increased plasma concentrations of BDNF (p=0.002) and IL-1β (p=0.005), suggesting their potential use for early identification.
Why the study?
Strong evidence was lacking on the link between inflammatory profiles and drug treatment response patterns in depressive patients that could lead to coronary artery disease.
Are subclinical atherosclerosis markers and inflammatory profiles altered in patients with Resistant Depression or Bipolar Affective Disorder compared to controls?
Observational (n=118)
Are subclinical atherosclerosis markers and inflammatory profiles altered in patients with Resistant Depression or Bipolar Affective Disorder compared to controls?
p-value: p=0.002 and 0.005
Elevated plasma BDNF and IL-1β concentrations may serve as early biomarkers for identifying patients with resistant depression, though subclinical atherosclerosis markers did not differ significantly except for reduced O2 consumption in BAD.
May aid biomarker research in resistant depression; hypothesis-generating and should not yet change practice.
BACKGROUND: There is no strong evidence on the link between inflammatory profile and pattern of drug treatment response in depressive patients that could result in Coronary Artery Disease occurrence. OBJECTIVE: This study aimed to compare the subclinical atherosclerosis markers, inflammatory profile, and BDNF production in Resistant Depression (RD) or Bipolar Affective Disorder (BAD) patients under conventional treatment. METHODS: The population evaluated was comprised of 34 RD, 43 BAD, and 41 controls. Subclinical atherosclerosis markers were evaluated using ultrasonography, tomography, and exercise stress test. Plasma concentrations of TNFα, IL-1β, IL-6, and BDNF were measured using Luminex100™. The usCRP concentration was measured using turbidimetric immunoassay. IL1B, IL6, and TNFA expression were determined using TaqMan®. For the statistical analysis, the significance level was established at p<0.05. RESULTS: Concerning subclinical atherosclerosis markers, only O2 consumption was reduced in the BAD group (p = 0.001). Although no differences were found in gene expression, BDNF and IL-1β plasma concentration was increased in the RD group (p = 0.002 and p = 0.005, respectively) even with an antidepressant treatment, which suggests that these drugs have no effect in IL-1β secretion and that the inflammasome may play a role in therapy response. CONCLUSION: Taken together, both BDNF and IL-1β plasma concentrations could be used to the early identification of RD patients.
No takes yet. Share an insight, caveat, or question.
Uint et al. (2019) conducted an observational in Resistant Depression and Bipolar Affective Disorder (n=118). Resistant Depression vs. Controls and Bipolar Affective Disorder patients was evaluated on BDNF and IL-1β plasma concentration (p=0.002 and 0.005). Resistant depression was associated with significantly increased plasma concentrations of BDNF (p=0.002) and IL-1β (p=0.005), suggesting their potential use for early identification.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: